Abstract

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy.

Is this guidance up to date?

Next review: More evidence on palbociclib is being collected until the ongoing PALOMA-3 clinical study concludes. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a patient access scheme and a commercial access agreement for palbociclib. Contact pfizerNICEaccount@pfizer.com for details.

Guidance development process

How we develop NICE technology appraisal guidance